Onconic Therapeutics Inc.
KOSDAQ-listed drug developer behind Zastaprazan, Korea's 37th approved new drug, and the dual-target anticancer candidate Nesuparib.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2020 and listed on KOSDAQ in 2024, Onconic Therapeutics is a small-molecule drug developer focused on gastrointestinal and oncology indications. Its P-CAB mechanism GI therapy Zastaprazan, Korea's 37th approved new drug, received marketing approval for erosive esophagitis and gastric ulcer and launched in October 2024, while its dual PARP/Tankyrase inhibitor Nesuparib is in development across multiple indications including a domestic Phase 2 trial for pancreatic cancer, a Phase 2 investigator-initiated trial for endometrial cancer (in combination with Keytruda), and IND approval for a Phase 1b/2 trial in gastric cancer. Zastaprazan was out-licensed for Greater China to China's Livzon Pharmaceutical Group Inc. in March 2023, and the company expanded out-licensing to India in May 2024.
Products & technology
- Zastaprazan (Jaqubo)P-CAB mechanism therapy for acid-related GI diseases (erosive esophagitis, gastric ulcer)
- NesuparibDual PARP/Tankyrase-inhibiting targeted anticancer agent
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2021 / 2 Korean MFDS drug approvals · 2024–2025
- OrphanJPI-5472021-04-27Orphan Drug designation · in development20210068545
- MFDS drugJAQBO ODT. 20mg (Zastaprazan citrate)2025-10-30Drug · Prescription · Approval202502813
- MFDS drugJAQBO Tab. 20mg(Zastaprazan citrate)2024-04-24Drug · Prescription · Approval202400960
Clinical trials
data.go.kr18 MFDS clinical trial authorisations · 2017–2026 (Phase 1 8 · Phase 3 5 · Phase 2 2 · Phase 1/2 2 · Phase 1b 1)
- Phase 3JP-1366 정2026-07-01
7 trial sites
- Phase 1JLP-23022026-06-02
2 trial sites
- Phase 1JPI-5472026-03-09
1 trial site
- Phase 2JPI-5472026-01-20
1 trial site
- Phase 1/2JPI-5472025-12-16
3 trial sites
- Phase 1/2JPI-5472025-09-29
8 trial sites
- Phase 1JP-1366 정2025-09-12
1 trial site
- Phase 3JP-1366 정2025-07-01
6 trial sites
- Phase 1JLP-23022024-12-04
2 trial sites
- Phase 3JP-1366 정2024-04-26
8 trial sites
- Phase 1JP-1366 정2023-01-16
- Phase 1JP-1366 정2022-09-01
Show 6 more
- Phase 2JPI-5472022-06-21
21 trial sites
- Phase 3JP-1366 정2022-05-31
11 trial sites
- Phase 1bJPI-5472022-01-28
7 trial sites
- Phase 3JP-1366 정2021-12-14
9 trial sites
- Phase 1JP-1366 정2021-01-15
1 trial site
- Phase 1JPI-5472017-10-30
6 trial sites
R&D and key agreements
Source: DART corporate disclosureNesuparib · 췌장암 · 국내 임상2상 진행중
Nesuparib · 자궁내막암 · 연구자주도 국내 임상2상(키트루다 병용)
Nesuparib · 위암 · 국내 임상1b/2상 IND 승인
Nesuparib · 난소암 · 국내 임상2상 IND 신청
OCNR-100/101/102/200/300 · 고형암 · 후보/선도물질 도출 단계 · Early-stage discovery pipeline candidates
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Spun off from Jeil Pharm Holdings in 2017, Jeil Pharmaceutical has licensed out its GERD drug Zastaprazan (Jaqubo) to multiple overseas partners.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition